Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical University, No. 393 Xinyi Road, Urumqi, 830054, Xinjiang, China.
The First Clinical Medical College, Xinjiang Medical University, Urumqi, 830054, China.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):6051-6059. doi: 10.1007/s00210-024-03014-w. Epub 2024 Feb 22.
Cysteine protease inhibitor S (CST4) plays a pivotal role in the regulation of growth, invasion, and metastasis of a variety of malignancies. However, the potential mechanism behind how CST4 contributes to CST4 in lymph node metastasis (LNM) and tumor-associated lymphangiogenesis of esophageal cancer (EC) cells has not been elucidated previously. Short hairpin RNA technique was utilized to upregulate the CST4 gene expression. Different experiments, including the tubule formation assay and immunofluorescence, were conducted to observe the cellular behavior. Enzyme-linked immunosorbent assay (ELISA) and Western blot analyses were employed to determine the expression levels of relevant proteins. In our study, we discovered that high expression of CST4 in EC cells had multiple effects. It stimulated cell proliferation, invasion, and migration and caused epithelial-mesenchymal transition (EMT). Moreover, it also inhibited the apoptosis of EC cells and caused them to stagnate in the G2/M phase. High expression of CST4 promoted the secretion of lymphangiogenic markers (TGFβ1, VEGF, VEGF-C/D) in EC cells. In addition, high expression of CST4 in EC cells not only enhanced the proliferation and migration of HLECs, but also stimulated the lumen formation and F-actin expression and rearrangement of HLECs. The elevated expression of CST4 also facilitated the secretion of p-ERK1/2, MMP9, and MMP-2 in HLECs. However, various tumor-promoting effects of high expression of CST4 on HLECs could be inhibited by VEGF inhibitors in EC cells. Overall, our findings indicate that CST4 plays a significant role in the accumulation, migration, and EMT of EC cells. CST4 can activate the VEGF-MAPK/ERK-MMP9/2 signaling axis to promote LNM and lymphangiogenesis in EC.
半胱氨酸蛋白酶抑制剂 S(CST4)在多种恶性肿瘤的生长、侵袭和转移的调节中起着关键作用。然而,以前尚未阐明 CST4 如何促进食管癌(EC)细胞淋巴结转移(LNM)和肿瘤相关淋巴管生成的潜在机制。本研究利用短发夹 RNA 技术上调 CST4 基因表达。通过管形成试验和免疫荧光等不同实验观察细胞行为。酶联免疫吸附试验(ELISA)和 Western blot 分析用于确定相关蛋白的表达水平。在我们的研究中,我们发现 EC 细胞中 CST4 的高表达具有多种作用。它刺激细胞增殖、侵袭和迁移,并导致上皮-间充质转化(EMT)。此外,它还抑制 EC 细胞的凋亡并导致它们停滞在 G2/M 期。CST4 的高表达促进了 EC 细胞中淋巴管生成标记物(TGFβ1、VEGF、VEGF-C/D)的分泌。此外,EC 细胞中 CST4 的高表达不仅增强了 HLEC 的增殖和迁移,还刺激了 HLEC 的管腔形成以及 F-肌动蛋白的表达和重排。CST4 的高表达还促进了 HLEC 中 p-ERK1/2、MMP9 和 MMP-2 的分泌。然而,EC 细胞中 CST4 的高表达对 HLEC 的各种促肿瘤作用可被 EC 细胞中的 VEGFR 抑制剂抑制。总之,我们的研究结果表明,CST4 在 EC 细胞的积聚、迁移和 EMT 中起重要作用。CST4 可以激活 VEGF-MAPK/ERK-MMP9/2 信号通路,促进 EC 中的 LNM 和淋巴管生成。
Naunyn Schmiedebergs Arch Pharmacol. 2024-8
Funct Integr Genomics. 2023-5-18
Aging (Albany NY). 2021-5-23
Clin Med Insights Oncol. 2025-1-6
Immunity. 2023-10-10
Physiol Rev. 2022-10-1
Clin Chim Acta. 2022-6-1
Acta Pharm Sin B. 2021-11
Dis Esophagus. 2021-10-11